Meta-analysis of effectiveness and safety of abciximab versus eptifibatide or tirofiban in percutaneous coronary intervention
- 1 March 2001
- journal article
- research article
- Published by Elsevier in The American Journal of Cardiology
- Vol. 87 (5) , 537-541
- https://doi.org/10.1016/s0002-9149(00)01427-2
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- Platelet Glycoprotein IIb/IIIa AntagonistsCirculation, 1999
- Quantifying GPIIb/IIIa Receptor Binding Using 2 Monoclonal AntibodiesCirculation, 1999
- Clinical Outcomes of Therapeutic Agents That Block the Platelet Glycoprotein IIb/IIIa Integrin in Ischemic Heart DiseaseCirculation, 1998
- Glycoprotein IIb/IIIa Integrin BlockadeCirculation, 1998
- Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockadeThe Lancet, 1998
- Platelet Glycoprotein IIb/IIIa Receptor Blockade and Low-Dose Heparin during Percutaneous Coronary RevascularizationNew England Journal of Medicine, 1997
- Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE studyThe Lancet, 1997
- Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of the Platelet Integrin Glycoprotein IIb/IIIa Blocker Integrelin in Elective Coronary InterventionCirculation, 1995
- Use of a Monoclonal Antibody Directed against the Platelet Glycoprotein IIb/IIIa Receptor in High-Risk Coronary AngioplastyNew England Journal of Medicine, 1994
- GPIIb-IIIa: The responsive integrinCell, 1991